How Much Does Metoprolol Raise Blood Sugar?

Metoprolol can raise blood sugar, but the effect is modest for most people. In clinical trials, patients on metoprolol typically see HbA1c increases on the order of 0.15 percentage points, and the drug’s influence on insulin sensitivity is real but not dramatic compared to the blood-sugar swings caused by diet, weight, or other medications. The story gets more interesting when you look at who is most affected, how metoprolol compares to other beta-blockers, and what your other medications might be doing to amplify or offset the problem.

Why Metoprolol Affects Blood Sugar at All

Beta-blockers as a class interfere with the body’s ability to manage glucose. They do this primarily by reducing insulin sensitivity, which means your cells become slightly less responsive to insulin’s signal to pull sugar out of the blood. Beta-blockers also blunt some of the hormonal responses that help regulate glucose release from the liver. These effects tend to be dose-dependent: higher doses cause more metabolic disruption.¹

Metoprolol is a “selective” beta-blocker, meaning it preferentially targets beta-1 receptors in the heart rather than beta-2 receptors found in the lungs, blood vessels, and liver. In theory, that selectivity should spare some of the metabolic pathways involved in blood sugar regulation. In practice, the selectivity is not absolute, especially at higher doses. That is why the metabolic effects still show up in studies, even if they tend to be milder than those seen with older, non-selective beta-blockers like propranolol or atenolol.

What the Numbers Actually Look Like

The most cited trial for metoprolol’s blood sugar effects is the GEMINI study, which directly compared metoprolol tartrate with carvedilol in people who already had type 2 diabetes and high blood pressure. After five months, the metoprolol group’s average HbA1c rose by 0.15 percentage points from baseline. That is a small but statistically real increase. By comparison, carvedilol barely budged HbA1c at all. Insulin sensitivity also worsened slightly with metoprolol but not with carvedilol.²

A 0.15% rise in HbA1c may not sound like much, and for most people, it is not. To put it in everyday terms, HbA1c reflects your average blood sugar over roughly three months. A jump of 0.15% translates to an average blood sugar increase of roughly 3 to 4 mg/dL. For someone whose diabetes is well-managed and whose HbA1c is comfortably within target, that small uptick is unlikely to change treatment decisions. For someone who is already teetering on the edge of their glucose goals, even a small nudge in the wrong direction could matter over years of treatment.

A separate study in people with metabolic syndrome compared metoprolol head-to-head with nebivolol, a newer beta-blocker. Metoprolol significantly reduced insulin sensitivity, while nebivolol had essentially no effect on it.³ This pattern keeps showing up: metoprolol is not the worst beta-blocker for blood sugar, but it is not the most metabolically friendly either.

Does Metoprolol Cause Diabetes in People Who Do Not Already Have It?

This is probably the question that worries people most. The COMET trial, one of the largest to address this directly, followed thousands of heart failure patients for years. Among those who did not have diabetes at the start of the study, about 12.6% in the metoprolol group developed new-onset diabetes, compared with about 10.3% in the carvedilol group.⁴ That gap is meaningful when spread across a large population, but it also means most people on metoprolol did not develop diabetes.

It is worth noting that the COMET trial used metoprolol tartrate (the short-acting form) rather than metoprolol succinate (the extended-release form), which behaves somewhat differently in the body. The formulation matters, and we will get to that shortly.

A broader look at beta-blockers in general, not just metoprolol, found that patients with stable coronary artery disease who were taking a beta-blocker had a meaningfully higher risk of developing new diabetes compared to those not on one. The risk was about 63% higher in the beta-blocker group. However, that elevated risk was largely neutralized when patients were also taking an ACE inhibitor.⁵ This is a useful finding for practical decision-making, because many people prescribed a beta-blocker for heart disease are also taking an ACE inhibitor or a similar drug.

Metoprolol Compared to Other Beta-Blockers

Not all beta-blockers behave the same way metabolically. The evidence consistently shows that carvedilol and nebivolol are friendlier to blood sugar than metoprolol. Carvedilol has additional properties beyond simple beta-blockade: it also blocks alpha-1 receptors, which appears to give it a mild insulin-sensitizing effect that counteracts the glucose-raising tendency shared by the class. In the GEMINI trial, carvedilol improved insulin sensitivity by about 9%, while metoprolol produced no meaningful change.²

Nebivolol, which works partly through nitric oxide signaling, also appears metabolically neutral. In the study comparing it with metoprolol in patients with metabolic syndrome, nebivolol caused essentially no change in insulin sensitivity, while metoprolol worsened it.³

However, a large real-world study of older adults with heart failure and diabetes complicated this picture somewhat. When researchers compared nearly 25,000 matched pairs of metoprolol users and carvedilol users, they found no significant difference in rates of new antidiabetic medication use, insulin initiation, or severe hyperglycemic events between the two groups.⁶ In other words, the metabolic advantage of carvedilol observed in controlled trials did not translate into a measurable clinical difference in this older, sicker population. This may mean that in practice, the blood sugar differences between the two drugs are small enough that other factors, like how well a patient tolerates the medication or how much it helps their heart condition, reasonably drive the choice.

Extended-Release Metoprolol Succinate vs. Short-Acting Tartrate

Most prescriptions for metoprolol today are for metoprolol succinate, the extended-release formulation, rather than metoprolol tartrate, the short-acting version. This distinction matters metabolically. A 12-week study specifically examined whether adding extended-release metoprolol succinate to existing therapy in people with type 2 diabetes changed their insulin sensitivity, blood lipids, or HbA1c. It did not. None of those metabolic markers moved significantly.⁷

Why might the formulation matter? Extended-release versions produce steadier drug levels in the blood, avoiding the peaks and troughs seen with short-acting versions. Those peaks can temporarily overwhelm beta-1 selectivity and start blocking beta-2 receptors too, which are more involved in glucose metabolism. A smoother drug level may allow the medication to do its cardiac job while leaving metabolic pathways less disturbed. The GEMINI trial and the COMET trial both used metoprolol tartrate, so their metabolic findings may overstate what happens with the extended-release form that most patients are actually prescribed.

Metoprolol and Hypoglycemia Recovery

For people with diabetes who take insulin, there is a separate and arguably more concerning issue than high blood sugar: metoprolol can interfere with the body’s ability to bounce back from low blood sugar. When blood glucose drops too low, the body normally responds with a surge of adrenaline that triggers the liver to release stored glucose. Beta-blockers dampen that adrenaline response.

A study in people with insulin-dependent diabetes found that metoprolol at 100 mg impaired recovery from insulin-induced hypoglycemia just as much as propranolol, a non-selective beta-blocker. This was surprising because metoprolol’s selectivity was expected to spare that recovery mechanism.⁸ Beta-blockers can also mask some of the warning signs of low blood sugar, particularly the rapid heartbeat that many people rely on as their earliest clue. Sweating, which is mediated by a different part of the nervous system, is typically not masked, so it becomes a more important warning signal for people on beta-blockers.

This does not mean people with diabetes cannot take metoprolol. It means they should be aware that their low-blood-sugar warning system may work differently, and their recovery from a low episode may be slower. That awareness is especially important for anyone who takes insulin or a sulfonylurea, both of which can cause hypoglycemia on their own.

Why the Same Dose Hits People Differently

Metoprolol is broken down in the liver by an enzyme called CYP2D6, and people carry different genetic versions of this enzyme. Some people are “poor metabolizers,” meaning their CYP2D6 works slowly or barely at all. For those individuals, a standard dose of metoprolol produces drug levels in the blood that are several times higher than what a normal metabolizer would experience from the same pill. A clinical pharmacogenetics guideline confirmed that CYP2D6 poor metabolizers have significantly greater exposure to metoprolol and a correspondingly larger heart rate reduction.⁹

Higher drug levels mean more beta-2 receptor blockade, which means more metabolic disruption. A person who is a CYP2D6 poor metabolizer taking a “normal” dose of metoprolol could experience blood sugar effects closer to what studies report at higher doses, even though their prescription looks routine. Roughly 5 to 10% of people of European descent fall into this category, though the proportion varies across different populations. Pharmacogenomic testing can identify these individuals, though such testing is not yet routine before prescribing metoprolol.

Drug interactions can mimic the same effect. Several common medications inhibit CYP2D6, effectively turning a normal metabolizer into a poor one. If you start a new medication and notice your blood sugar creeping up while your metoprolol dose has not changed, a drug interaction affecting how your body processes metoprolol could be part of the explanation.

The ACE Inhibitor Buffer

One of the more actionable findings in this area is that ACE inhibitors appear to counteract the diabetes-promoting effect of beta-blockers. In a study of patients with stable coronary artery disease, the elevated risk of new-onset diabetes associated with beta-blocker use essentially disappeared when patients were also taking the ACE inhibitor trandolapril.⁵ ARBs, a related class of blood pressure drugs, appear to have similar protective metabolic effects, though the evidence is not as direct for this specific pairing.

This matters because the combination of a beta-blocker and an ACE inhibitor is already standard treatment for many cardiac conditions. If you are on metoprolol for heart failure or after a heart attack, there is a good chance you are also taking an ACE inhibitor or an ARB, which may already be blunting whatever blood sugar effect metoprolol would otherwise cause. The metabolic concern becomes most relevant for people taking metoprolol by itself for conditions like isolated high blood pressure or migraine prevention, where an ACE inhibitor is not automatically part of the regimen.

Dose Dependence and the Higher-Dose Question

The metabolic effects of beta-blockers, including metoprolol, tend to worsen as the dose climbs. This is partly because metoprolol’s selectivity for beta-1 receptors is dose-dependent: at low to moderate doses, it mostly leaves beta-2 receptors alone, but at higher doses, it increasingly blocks beta-2 as well. A small study in heart failure patients showed that as metoprolol doses were titrated up to 100 mg and 200 mg daily, measurable changes in glucose handling appeared that were not evident at lower doses.¹⁰

For practical purposes, this means the blood sugar impact of metoprolol at 25 mg or 50 mg daily, which are common starting doses for blood pressure control, is likely smaller than what clinical trials conducted at higher doses report. If your doctor has you on a low dose and your blood sugar is well-controlled, the metabolic effect may be negligible. The concern grows more relevant for people on 100 mg, 200 mg, or higher doses, which are more common in heart failure management.

Monitoring and What to Watch For

If you are starting metoprolol and you have diabetes or prediabetes, periodic blood sugar monitoring is reasonable, especially in the first few months. A fasting glucose check and HbA1c measurement before starting the drug give your doctor a baseline to compare against. Repeating the HbA1c after three to six months of treatment can reveal whether metoprolol is nudging your numbers in the wrong direction.

For people without diabetes, the risk of metoprolol tipping you into a diabetic range is real but small, as the COMET data suggest. Your baseline risk factors matter: if you already have prediabetes, a family history of diabetes, or metabolic syndrome, you are on more vulnerable ground. In those situations, your doctor might choose a beta-blocker with a more neutral metabolic profile, like carvedilol or nebivolol, when the clinical situation allows it.

Weight gain is another metoprolol side effect that can indirectly worsen blood sugar control. Beta-blockers tend to reduce energy expenditure slightly and can make exercise feel harder by limiting heart rate response. The combination of a few extra pounds and slightly reduced insulin sensitivity can compound over time in a way that neither effect would produce alone. Staying physically active and watching caloric intake while on metoprolol is one of the more practical things you can do to offset its metabolic effects, even though the drug may make vigorous exercise feel less comfortable than it used to.